agilon health, inc. (AGL) experienced a significant pre-market plunge of 17.63% on Wednesday, following the company's mixed fourth-quarter 2024 earnings results and disappointing guidance for the upcoming fiscal year 2025.
While the healthcare services company reported strong revenue growth of 44% year-over-year in Q4 2024, reaching $1.52 billion, its earnings metrics fell short of expectations. agilon health reported an adjusted loss per share of $0.26, wider than analysts' estimates, and an adjusted EBITDA loss of $83.97 million, significantly lagging projections.
However, the primary concern for investors appears to be the company's weak outlook for fiscal 2025. agilon health provided revenue growth guidance of just -2.2% year-over-year at the midpoint, a sharp deceleration from the impressive 40.7% growth achieved in 2024. Additionally, the projected 2025 adjusted EBITDA guidance of -$75 million fell short of expectations, highlighting continued profitability challenges amid what management termed a "challenging Medicare Advantage environment."
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。